Morgan Stanley Shares What Johnson & Johnson Investors Should Focus On Now

In a report published Wednesday, analysts at Morgan Stanley maintain their Equal-Weight rating on Johnson & Johnson JNJ. The company reported its 1Q results, with Devices largely in line with the estimates and the Pharma segment beating the consensus. The company growth trajectory is still the source of speculation, given its 1Q results. The analysts said that most of the upside, relative to the consensus, was driven by Pharma. The company has revised its EPS guidance down, in line with the estimates.